Sarbani Chaudhuri Sells 17,650 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Posted by Francis Steltz on May 13th, 2026

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) insider Sarbani Chaudhuri sold 17,650 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $3.84, for a total value of $67,776.00. Following the sale, the insider owned 267,510 shares of the company’s stock, valued at approximately $1,027,238.40. The trade was a 6.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ RCKT opened at $3.64 on Wednesday. Rocket Pharmaceuticals, Inc. has a 12 month low of $2.19 and a 12 month high of $7.14. The company has a market cap of $397.45 million, a P/E ratio of -1.95 and a beta of 0.52. The business’s 50 day moving average is $4.03 and its two-hundred day moving average is $3.68. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.08.

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). During the same quarter in the prior year, the company earned ($0.56) earnings per share. On average, equities analysts expect that Rocket Pharmaceuticals, Inc. will post -1.55 EPS for the current year.

Key Stories Impacting Rocket Pharmaceuticals

Here are the key news stories impacting Rocket Pharmaceuticals this week:

Positive Sentiment: Chardan Capital reaffirmed its Buy rating on Rocket Pharmaceuticals and maintained an $11.00 price target, suggesting meaningful upside from current levels. Article Title
Positive Sentiment: Lifesci Capital still has a Strong-Buy rating on Rocket Pharmaceuticals, even after adjusting some quarterly estimates, indicating continued analyst support for the name.
Neutral Sentiment: Lifesci Capital raised its Q2 2026 EPS estimate for Rocket Pharmaceuticals to $1.02 from a prior loss estimate, partially offsetting weaker expectations for later quarters.
Neutral Sentiment: Insider Sarbani Chaudhuri sold 17,650 shares, but the company said the sale was made to cover tax withholding obligations tied to equity vesting, which reduces the signal for investors. Article Title
Negative Sentiment: Lifesci Capital lowered its Q3 2026 and Q4 2026 EPS estimates for Rocket Pharmaceuticals, reinforcing concerns that profitability may remain under pressure.
Negative Sentiment: The company’s Q1 earnings miss and the market’s focus on the commercial launch of Kresladi have weighed on sentiment, as investors wait for proof of execution. Article Title

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RCKT shares. Chardan Capital reaffirmed a “buy” rating and set a $11.00 price objective on shares of Rocket Pharmaceuticals in a research report on Monday. Weiss Ratings raised Rocket Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Cantor Fitzgerald boosted their price target on Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. The Goldman Sachs Group upped their price target on Rocket Pharmaceuticals to $3.00 and gave the company a “sell” rating in a report on Monday, March 2nd. Finally, Lifesci Capital raised Rocket Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Rocket Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $11.54.

Read Our Latest Stock Report on RCKT

Institutional Trading of Rocket Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Prudential Financial Inc. bought a new position in Rocket Pharmaceuticals during the second quarter worth about $25,000. Franklin Resources Inc. acquired a new stake in Rocket Pharmaceuticals during the fourth quarter valued at approximately $38,000. Sequoia Financial Advisors LLC bought a new stake in shares of Rocket Pharmaceuticals in the 4th quarter valued at approximately $42,000. CANADA LIFE ASSURANCE Co raised its holdings in shares of Rocket Pharmaceuticals by 94.4% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock worth $29,000 after buying an additional 5,926 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Rocket Pharmaceuticals in the 3rd quarter worth approximately $40,000. Institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Company Profile

(Get Free Report)

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.